With the recent success of clinically-approved ADCs in MM, such as Blenrep (anti-BCMA) [14], and other ADCs undergoing clinical trial, such as IMGN901 (anti-CD56) [15], the potential of ADCs and similar immunoconjugates will be increasingly evaluated in such heavily pretreated MM patients. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.